SF0166
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for SF0166, covering 2023-05-11 to 2023-06-07. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD) [Phase 1, Phase 2]